CD19-Directed Monoclonal Antibody (Fc-Enhanced) Pregnancy: Contraindicated (tafasitamab + lenalidomide combination — lenalidomide is teratogenic); strict pregnancy prevention required

Tafasitamab

Brand names: Minjuvi

Adult dose

Dose: 12 mg/kg IV; induction: cycles 1-3 (D1, D4, D8, D15, D22); maintenance: cycles 4+ (D1, D8, D15)

Route: Intravenous infusion

Frequency: Per cycle schedule; 28-day cycles

Max: 12 mg/kg per dose

With lenalidomide for R/R DLBCL not eligible for ASCT; lenalidomide given 25 mg PO D1-21; continue tafasitamab monotherapy after lenalidomide completion until progression

Paediatric dose

Dose: Not established N/A/kg

Route: N/A

Frequency: N/A

Max: N/A

Not licensed in paediatrics

Dose adjustments

Renal

No dose adjustment for CrCl ≥30 mL/min; limited data below

Hepatic

No formal adjustment required

Paediatric weight-based calculator

Patient weight (kg)

Not licensed in paediatrics

Clinical pearls

L-MIND trial (Salles et al. Lancet Oncol 2020): tafasitamab + lenalidomide achieved 57.5% ORR with 40% CR rate in R/R DLBCL — particularly impressive in transplant-ineligible patients
Fc-engineering (XMAB® technology) enhances ADCC and ADCP activity versus standard anti-CD19 antibodies; tafasitamab monotherapy continues after lenalidomide to maintain CD19 depletion
MHRA 2021 approved; NICE TA739 for R/R DLBCL not eligible for ASCT — complements the R/R DLBCL treatment landscape alongside polatuzumab-bendamustine-rituximab
Lenalidomide mandatory REMS in UK: pregnancy prevention programme (male and female); negative pregnancy test required; contraception for females of childbearing age
Prolonged B-cell depletion expected — immunoglobulin monitoring recommended; consider IVIG replacement for recurrent/severe infections; vaccinations should be given before treatment if possible

Contraindications

Known hypersensitivity to tafasitamab or murine proteins
Lenalidomide-specific contraindications apply when combined

Side effects

Neutropenia (most common grade 3-4 toxicity)
Thrombocytopenia
Anaemia
Infusion-related reactions
Fatigue
Diarrhoea
Peripheral oedema
Infections (including opportunistic)

Interactions

Lenalidomide — combination regimen; lenalidomide-specific interactions apply (thalidomide analogue, thrombosis risk)
Live vaccines — avoid; profound B-cell depletion
Immunosuppressants — additive immunosuppression

Monitoring

FBC (before each cycle)
Immunoglobulin levels (every 3-4 months)
Infusion reactions (vital signs during and 1 hour post-infusion)
DVT/PE (thrombosis risk with lenalidomide)
Infection surveillance

Reference: BNFc; BNF 90; L-MIND trial (Salles et al. Lancet Oncol 2020); NICE TA739; MHRA SPC Minjuvi; RE-MIND2 study (Duell et al. Haematologica 2021). Verify against your local formulary and the latest BNF before prescribing.

Curated clinical cross-links plus same-class fallbacks.

Pathways